Evidence map›Paper›PMID 40599122›Full record

ArticleAnnals of clinical and translational neurology2025

High-Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies-A Real-World Study.

Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiang LiDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Binbin XueDepartment of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jia LiDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Dewei XieDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Juyuan PanDepartment of Neurology, Taizhou Hospital, Linhai, China.
Lanbing ZhuDepartment of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Qiaowen TongDepartment of Neurology, Wenzhou People's Hospital, Wenzhou, China.
Jing LinDepartment of Neurology, Ruian People's Hospital, Ruian, China.
Xu ZhangDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.ORCID 0000-0002-3680-513X
Junhui XiaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jie LinDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.ORCID 0000-0001-6055-5903

Funding

Wenzhou Municipal Science and Technology Bureau Y20210168
6 · The paper itself

Abstract

objectiveTo compare the effectiveness of high-efficacy treatments (HET) and low-efficacy treatments (LET) in NMOSD patients with anti-aquaporin-4 antibodies (AQP4-ab).

methodsIn this multi-center study, we analyzed 183 AQP4-ab seropositive NMOSD patients who received immunosuppressive treatments (IST). Primary outcomes included annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS).

resultsA total of 86 HET and 143 LET treatment episodes were included. Patients with HET had the lower relapse rate (41.9% vs. 59.4%, p = 0.015). At the final follow-up, the HET group had lower ARR (p = 0.003) and EDSS (p = 0.004) compared to LET. HET (p < 0.001, adjusted p < 0.001), early IST initiation after onset (p = 0.007, adjusted p = 0.008) and younger age of onset (p = 0.024, adjusted p = 0.028) were the protective factors for high EDSS, and HET (HR: 0.66, 95% CI: 0.44-0.99, p = 0.047) prolonged the remission after IST. Meantime, Anderson-Gill analysis indicated that HET is associated with a lower risk of relapse (p < 0.001). After PSM, patients receiving HET had significantly reduced ARR (p = 0.046) and EDSS scores (p =0.030) compared to those receiving LET.

interpretationOur findings indicated the superior efficacy in reducing neurological disability and relapse risk of HET in AQP4-ab seropositive NMOSD patients.

Indexed as

Aquaporin 4AutoantibodiesImmunosuppressive AgentsNeuromyelitis OpticaAdultFemaleHumansMaleMiddle AgedRecurrenceAQP4 protein, humanAquaporin 4AutoantibodiesImmunosuppressive AgentsAQP4 antibodiesARREDSShigh‐efficacy treatmentneuromyelitis optica spectrum disorder

Identifiers

PMID40599122
PMCPMC12516220

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.